Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion

Circulation

Volumn 103, Issue 17, 2001, Pages 2181-2187

  Lindsey, Merry ^a,d   Wedin, Kyle ^a,d   Brown, Michael D ^b,d   Keller, Christopher ^a,d   Evans, Alida J ^a,d   Smolen, James ^c,d   Burns, Alan R ^a,d   Rossen, Roger D ^b,d   Michael, Lloyd ^a,d   Entman, Mark ^a,d,e  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MS F602 ^*  (United States)

Author keywords

Blood cells; Ischemia; Metalloproteinases; Reperfusion

Indexed keywords

COLLAGEN; FIBRONECTIN; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME RELEASE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; IMMUNOCHEMISTRY; LYMPH; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT; TISSUE REPAIR; ZYMOGRAPHY;

EID: 6644223404     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.17.2181     Document Type: Article

References (45)

1. Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269:H2147-H2154.
2. Kukielka GL, Youker KA, Michael LH, et al. Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Mol Cell Biochem. 1995;147:5-12.
3. Kukielka GL, Entman ML. Adhesion molecule-dependent cardiovascular injury. In: Metcalf BW, Dalton BJ, Poste G, eds. Cellular Adhesion: Molecular Definition to Therapeutic Potential. New York, NY: Plenum Press; 1994:187-212.
4. Hawkins HK, Entman ML, Zhu JY, et al. Acute inflammatory reaction after myocardial ischemic injury and reperfusion: development and use of a neutrophil-specific antibody. Am J Pathol. 1996;148:1957-1969.
5. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994;28: 1301-1311.
6. Matsumura K, Jeremy RW, Schaper J, et al. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998; 97:795-804.
7. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503-3521.
8. Dreyer WJ, Smith CW, Michael LH, et al. Neutrophil accumulation in ischemic canine myocardium. Circulation. 1991;84:400-411.
9. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation. 1976; 53(suppl I):I-204-I-206.
10. Hammerman H, Kloner RA, Hale S, et al. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation and ventricular function. Circulation. 1983;68:446-452.
11. Dreyer WJ, Smith CW, Michael LH, et al. Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium. Circ Res. 1989;65:1751-1762.
12. Dreyer WJ, Michael LH, Nguyen T, et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res. 1992;71:1518-1524.
13. Rossen RD, Michael LH, Kagiyama A, et al. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res. 1988;62:572-584.
14. Michael LH, Lewis RM, Brandon TA, et al. Cardiac lymph flow in conscious dogs. Am J Physiol. 1979;6:H311-H317.
15. Michael LH, Hunt JR, Weilbaecher D, et al. Creatine kinase and phosphorylase in cardiac lymph: coronary occlusion and reperfusion. Am J Physiol. 1985;248:H350-H359.
16. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem. 1993;26:191-198.
17. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
18. Every D. Quantitative measurement of protease activities in slab polyacrylamide gel electrophoretograms. Anal Biochem. 1981;116:519-523.
19. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994;218:325-329.
20. Kjeldsen L, Bainton DF, Sengelov H, et al. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation. Blood. 1993;82:3183-3191.
21. Mollinedo F, Schneider DL. Intracellular organelle motility and membrane fusion processes in human neutrophils upon cell activation. FEBS Lett. 1987;217:158-162.
22. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol. 1999;65:137-150.
23. Owen CA, Campbell EJ. Neutrophil proteinases and matrix degradation: the cell biology of pericellular proteolysis. Semin Cell Biol. 1995;6: 367-376.
24. Morel F, Dewald B, Berthier S, et al. Further characterization of the gelatinase-containing particles of human neutrophils. Biochim Biophys Acta. 1994;1201:373-380.
25. Porteu F, Nathan CF. Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils. J Leukoc Biol. 1992;52: 122-124.
26. Hamilton JR, Hart JL, Woodman OL. Degranulation enhances release of a stable contractile factor from rabbit polymorphonuclear leukocytes. Am J Physiol. 1998;274:H1545-H1551.
27. Pontremoli S, Melloni E. The role of intracellular proteinases in human neutrophil activation. Rev Biol Cel. 1989;20:161-177.
28. McMillan WD, Tamarina NA, Cipollone M, et al. The relationship between MMP-9 expression and aortic diameter. Circulation. 1997;96: 2228-2232.
29. Opdenakker G. On the roles of extracellular matrix remodeling by gelatinase B. Verh K Acad Geneeskd Belg. 1997;59:489-514.
30. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998;274: R1203-R1211.
31. Fowlkes JL, Thrailkill KM, Serra DM, et al. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res. 1995;6:255-263.
32. Suzuki M, Raab G, Moses MA, et al. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997;272:31730-31737.
33. Crowe PD, Walter BN, Mohler KM, et al. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 1995;181:1205-1210.
34. Orlando S, Sironi M, Bianchi G, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem. 1997;272: 31764-31769.
35. Gallea-Robache S, Morand V, Millet S, et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine. 1997;9:340-346.
36. Mullberg J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol. 1995;155:5198-5205.
37. Levi E, Fridman R, Miao H-Q, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996;93:7069-7074.
38. Smith MR, Kung H, Durum SK, et al. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine. 1997;9:770-780.
39. Lombard MA, Wallace TL, Kubicek MF, et al. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res. 1998;58:4001-4007.
40. Mullberg J, Dittrich E, Graeve L, et al. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett. 1993;332:174-178.
41. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340-3346.
42. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1β by matrix metalloproteinases. J Biol Chem. 1996;271:14657-14660.
43. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999:103: 1237-1241.
44. Richard V, Murry CE, Reimer KA. Healing of myocardial infarcts in dogs. Circulation. 1995;92:1891-1901.
45. Swan HJC. Left ventricular dysfunction in ischemic heart disease: fundamental importance of the fibrous matrix. Cardiovasc Drugs Ther. 1994;8:305-312.